Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 18/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.33 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.33 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.33 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17892737 | 1.00 | TNK2 (0.37) | TNK2PIK3CAPIK3CBMTORPIK3CG | |
| SCHEMBL23042158 | 0.84 | TNK2 (0.42) | TNK2IGF1R | |
| SCHEMBL16748883 | 0.84 | TNK2 (0.42) | TNK2IGF1R | |
| SCHEMBL25277349 | 0.81 | PIK3CA (0.49) | TNK2PIK3CAPIK3CBMTORPIK3CG | |
| SCHEMBL25277348 | 0.81 | PIK3CA (0.49) | TNK2PIK3CAPIK3CBMTORPIK3CG | |
| SCHEMBL18099736 | 0.81 | TNK2 (0.41) | TNK2IGF1R | |
| SCHEMBL14631362 | 0.81 | TNK2 (0.48) | TNK2IGF1R | |
| SCHEMBL14630272 | 0.81 | TNK2 (0.48) | TNK2IGF1R | |
| SCHEMBL17893125 | 0.81 | TNK2 (0.45) | TNK2PIK3CAPIK3CBMTORPIK3CG | |
| SCHEMBL17892415 | 0.81 | TNK2 (0.45) | TNK2PIK3CAPIK3CBMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349593-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-07 | — | — | US | disclosed |
| EP-3240544-A2 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109217-A2 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349593-A1 | BTK INHIBITORS | BTK, SYK, LYN | TNK2 183/4885PIK3CA 51/4885PIK3CB 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.